TARRYTOWN, N.Y., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new analyses of EYLEA HD® (aflibercept) Injection 8 mg and EYLEA® (aflibercept) ...
In the United States, aflibercept-yszy received Food and Drug Administration (FDA) approval in May 2024 as a biosimilar to ...
Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...
The MHRA has granted marketing authorisation for Eylea® (aflibercept 8 mg) for the treatment of patients with macular oedema following retinal vein occlusion (RVO) including branch, central and ...
More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...
P041, an aflibercept biosimilar, showed noninferiority to originator aflibercept (Eylea) in maintaining vision in nAMD patients over 52 weeks. The study involved 168 patients, with 145 completing the ...
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced the presentation of 27 abstracts, including eight oral sessions, featuring EYLEA HD (aflibercept) Injection 8 mg at the upcoming ARVO 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results